

# Latest infection status, etc. (1)

## ○ Trends in the numbers of new cases of infection

(Per 100,000 of the population)

	11/10-11/16			11/17~11/23			11/24~11/30		
Nationwide	0.91	(1,146)	↓	0.72	(908)	↓	0.54	(681)	↓
Hokkaido	1.98	(104)	↑	2.55	(134)	↑	1.39	(73)	↓
Saitama	1.03	(76)	↑	0.65	(48)	↓	0.68	(50)	↑
Chiba	0.81	(51)	→	0.48	(30)	↓	0.35	(22)	↓
Tokyo	1.05	(146)	↓	0.88	(122)	↓	0.75	(105)	↓
Kanagawa	1.10	(101)	↑	1.21	(111)	↑	0.74	(68)	↓
Aichi	0.86	(65)	↓	0.68	(51)	↓	0.60	(45)	↓
Kyoto	1.39	(36)	↑	1.05	(27)	↓	0.35	(9)	↓
Osaka	2.10	(185)	↓	1.42	(125)	↓	1.01	(89)	↓
Hyogo	1.23	(67)	↓	0.55	(30)	↓	0.59	(32)	↑
Fukuoka	0.84	(43)	↑	1.29	(66)	↑	0.61	(31)	↓
Okinawa	1.10	(16)	↓	0.48	(7)	↓	0.83	(12)	↑

## ○ Trends in the testing system

(Number of tests, positive rate)

	11/1~11/7		11/8~11/14			11/15~11/21		
Nationwide	261,560↓	0.5% ↓	266,449↑	0.5% ↓	275,273↑	0.4% ↓		
Hokkaido	14,602↑	0.5% ↑	14,863↑	0.6% ↑	13,596↓	1.1% ↑		
Saitama	21,030↓	0.2% ↓	14,436↓	0.5% ↑	14,186↓	0.4% ↓		
Chiba	9,929↓	0.6% ↑	11,156↑	0.5% ↓	11,276↑	0.3% ↓		
Tokyo	42,721↓	0.3% ↑	43,699↑	0.4% ↑	57,207↑	0.2% ↓		
Kanagawa	15,514↓	0.5% ↑	15,648↑	0.6% ↑	16,101↑	0.7% ↑		
Aichi	9,366↓	0.9% ↓	8,857↓	0.7% ↓	8,406↓	0.5% ↓		
Kyoto	4,512↓	0.6% ↓	5,004↑	0.8% ↑	4,375↓	0.7% ↓		
Osaka	34,420↓	0.7% ↓	45,600↑	0.5% ↓	39,301↓	0.3% ↓		
Hyogo	8,437↓	1.1% ↓	7,457↓	1.0% ↓	9,219↑	0.4% ↓		
Fukuoka	11,751↓	0.3% ↓	11,732↓	0.3% ↓	11,345↓	0.6% ↑		
Okinawa	6,138↓	0.8% ↑	3,534↓	0.5% ↓	7,208↑	0.1% ↓		

\* ↑, ↓, and → indicate an increase, a decrease, and the same level, respectively, compared to the previous week.

# Latest infection status, etc. (2)

## ○ Trends in the numbers of inpatients

[No. of inpatients (Ratio to the no. of secured beds)]

	11/10		11/17		11/24	
Nationwide	750 (1.9%) ↓		601 (1.5%) ↓		523 (1.3%) ↓	
Hokkaido	17 (0.9%) ↓		26 (1.3%) ↑		65 (3.3%) ↑	
Saitama	42 (2.4%) ↓		58 (3.3%) ↑		50 (2.8%) ↓	
Chiba	20 (1.5%) ↓		21 (1.6%) ↑		12 (0.9%) ↓	
Tokyo	113 (1.7%) ↓		96 (1.4%) ↓		66 (1.0%) ↓	
Kanagawa	59 (3.0%) ↓		55 (2.8%) ↓		64 (3.0%) ↑	
Aichi	35 (2.2%) ↑		16 (1.0%) ↓		11 (0.7%) ↓	
Kyoto	13 (1.8%) ↓		15 (2.0%) ↑		28 (3.8%) ↑	
Osaka	143 (4.0%) ↑		118 (3.3%) ↓		78 (2.2%) ↓	
Hyogo	44 (3.2%) ↓		38 (2.8%) ↓		33 (2.4%) ↓	
Fukuoka	10 (0.7%) ↓		9 (0.6%) ↓		18 (1.2%) ↑	
Okinawa	10 (1.6%) ↓		5 (0.8%) ↓		1 (0.2%) ↓	

## ○ Trends in the numbers of severe patients


[No. of inpatients (Ratio to the no. of secured beds)]

	11/10		11/17		11/24	
Nationwide	133 (2.4%) ↓		95 (1.7%) ↓		78 (1.4%) ↓	
Hokkaido	1 (0.7%) →		1 (0.7%) →		2 (1.5%) ↑	
Saitama	13 (7.1%) ↓		10 (5.5%) ↓		8 (4.4%) ↓	
Chiba	1 (0.9%) ↓		1 (0.9%) →		0 (0.0%) ↓	
Tokyo	50 (4.1%) ↑		37 (3.1%) ↓		32 (2.7%) ↓	
Kanagawa	7 (3.3%) ↓		7 (3.3%) →		5 (2.4%) ↓	
Aichi	4 (2.3%) →		2 (1.2%) ↓		2 (1.2%) →	
Kyoto	0 (0.0%) ↓		0 (0.0%) →		0 (0.0%) →	
Osaka	38 (2.9%) ↓		21 (1.6%) ↓		18 (1.4%) ↓	
Hyogo	4 (2.8%) ↑		4 (2.8%) →		4 (2.8%) →	
Fukuoka	4 (2.0%) ↓		4 (2.0%) →		4 (2.0%) →	
Okinawa	3 (5.0%) ↑		0 (0.0%) ↓		0 (0.0%) →	


\* “Trends in the numbers of inpatients” are based on the “Surveillance of the Status of Care for Patients with the Novel Coronavirus Infection and the Number of Beds,” by the Ministry of Health, Labour and Welfare. In this surveillance, the results as of 0:00 on the presentation date are published.

↑, ↓, and → indicate an increase, a decrease, and the same level, respectively, compared to the previous week.


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated December 1, 2021


1) No. of new cases of infection reported




2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




3) Test status




4) No. of inpatients/No. of severe patients









5) Use rate of beds




6) No. of patients receiving treatment









(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated December 1, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated December 1, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds









(6) No. of patients receiving treatment




(Source) ADB Material, dated December 1, 2021







(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients




(5) Use rate of beds




(6) No. of patients receiving treatment




(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated December 1, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated December 1, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment







(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status



(4) No. of inpatients/No. of severe patients



(5) Use rate of beds



(6) No. of patients receiving treatment

